目的 探討氨磷汀聯(lián)合多西他賽和卡鉑治療卵巢癌的臨床療效。方法 選取2012年2月—2016年2月在南陽市中心醫(yī)院進(jìn)行治療的卵巢癌患者80例，隨機(jī)分為對照組（40例）和治療組（40例）。對照組靜脈滴注多西他賽注射液，75 mg/m²加入500 mL生理鹽水，同時(shí)靜脈滴注注射用卡鉑，300~400 mg/m²加入500 mL生理鹽水，1次/28 d；治療組在對照組的基礎(chǔ)上于化療前30 min靜脈滴注注射用氨磷汀，500~600 mg/m²加入500 mL生理鹽水，15 min滴完，1次/28 d。兩組患者均治療3次。觀察兩組患者臨床療效，比較治療前后兩組患者腫瘤標(biāo)志物水平、QLQ-C30功能領(lǐng)域評分和不良反應(yīng)情況。結(jié)果 治療后，對照組臨床有效率（ORR）和疾病控制率（CBR）分別為52.50%、82.50%，均顯著低于治療組的57.50%、87.50%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后兩組患者血清癌胚抗原（CEA）、糖蛋白125（CA125）、糖蛋白199（CA199）和糖蛋白153（CA153）均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組患者QLQ-C30功能領(lǐng)域評分明顯升高（P < 0.05），且治療組QLQ-C30功能領(lǐng)域各評分比對照組升高更顯著（P < 0.05）。治療期間，對照組不良反應(yīng)發(fā)生率為47.50%，明顯高于治療組的20.00%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 氨磷汀聯(lián)合多西他賽和卡鉑治療卵巢癌可有效降低化療毒副作用，改善患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the efficacy of amifostine combined with docetaxel and carboplatin in treatment of ovarian cancer. Methods Patients (80 cases) with ovarian cancer in Nanyang City Central Hospital from February 2012 to February 2016 were randomly divided into control (40 cases) and treatment (40 cases) groups. Patients in the control group were iv administered with Docetaxel Injection, 75 mg/m² added into normal saline 500 mL, at the same time they were iv administered with Carboplatin for injection, 300 — 400 mg/m² added into normal saline 500 mL, once every 28 d. Patients in the treatment group were iv administered with Amifostine for injection on the basis of the control group 30 min before chemotherapy, 500 — 600 mg/m² added into normal saline 50 mL, dripped in 15 min, once every 28 d. Patients in two groups were treated for 3 times. After treatment, the clinical efficacy was evaluated, and the tumor markers, QLQ-C30 scores and adverse reactions in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 52.50% and 82.50%, which were significantly lower than 57.50% and 87.50% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the CA125, CA199, CA153, and CEA levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the QLQ-C30 functional scores in two groups were significantly increased (P < 0.05), and QLQ-C30 functional scores in the treatment group were significantly higher than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 47.50%, which was significantly higher than 20.00% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Amifostine combined with docetaxel and carboplatin can effectively reduce the chemotherapy side effect and improve the quality of life in treatment of ovarian cancer, which has a certain clinical application value.